Virtual ISPOR European 2020

The Virtual ISPOR Europe 2020 will be commencing next week. A number of OHE researchers will be in attendance to present their research.

With the theme Improving Health: Establishing Incentives and Sharing Value, Virtual ISPOR Europe 2020 will question the fundamental conventions around value, risk, rewards, and the role of public and private sectors.   

This event provides dedicated opportunities to network with peers, HEOR experts, thought leaders, and to discuss how to establish, incentivise and share values sustainable for health systems, patients, and technology developers with a global audience.

Please see below for information on presentations by OHE participants:

Friday 13th November 10, 2020

Time: 13:30 – 15:00

Note: The ISPOR Issue Panel on demand session on cost-effectiveness thresholds, value-based pricing and market allocative efficiency will be repeated to allow audience to post questions to panellists in a live Q&A session Value-Based Pricing and Market Allocative Efficiency: How Should Cost-Effectiveness Thresholds be Set to “Optimally” Distribute Value between Payers and Developers? – available to registered attendees

Mikel Berdud, PhD, MSc

Senior Principal Economist, Office of Health Economics

Panellist of ISPOR Europe Issue Panel

In the session the panel discussed the implications of setting CETs for value distribution between payers (consumers) and developers (producers). They debated how CETs should be determined and Nancy Devlin introduced the issue and moderated the panel, ensuring debate and audience participation. In this On-Demand repeated session the panellists will be live to answer questions

 

Wednesday 18th November 2020

Time: 15:00 – 16:30

Bridging the Gap- Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies

Lotte Steuten, PhD, MSc

Vice President and Head of Consulting, Office of Health Economics

Moderator 

Lotte will moderate this Educational Symposium where panellists will provide an insight into the current regulatory and HTA landscape for histology-independent therapies in various countries in North America, Europe and Asia, and discuss how to move forward from here. Global experts on histology-independent therapies will present their insights and discuss how to make a positive change from a patient representative perspective, a medical perspective and an HTA and policy perspective.

 

Pre-recorded sessions:  available now to registered attendees

Developments in HTA processes and methods

Marina Rodes Sanchez, MSc

Senior Economist, Office of Health Economics

Panellist: on demand podium session

Marina presents an in-depth analysis by the OHE on Adaptive Pathways for Tumour Agnostic Medicines in Various Developed Markets. While challenges for Tumour Agnostic medicines are similar in various countries, solutions will likely have to be diverse and include methodological advancements, novel payment models and decision-makers’ willingness to adopt new approaches. This presentation provides recommendations on each of these to further stimulate dialogue between the various stakeholders involved.

 

Pre-recorded sessions:  available now to registered attendees

A longer life or a quality death? A discrete choice experiment to estimate the relative importance of different aspects of end-of-life care

Chris Skedgel, PhD, MDE

Associate Director, Office of Health Economics

Presenter

Using discrete choice methods, Chris and his co-author find that a majority of the public prioritise good relations with family and a sense of dignity and control over survival gains at end-of-life. This may have implications for how we value end-of-life care using time-based measures such as the QALY.

 

Impact of Including Caregiver Information in Time Trade-Off Tasks: Results from a Pilot Study

David Mott, PhD, MSc

Senior Economist, Office of Health Economics

Co-Author

This poster by David Mott and co-authors presents the results of a pilot health state valuation study that explored the feasibility of investigating whether participants implicitly consider the impact of the health state on others. Two time trade-off exercises were conducted with participants, one following the traditional approach, and one that provided contextual information about the need for a carer, and the carer’s health state. The task was feasible to conduct in practice but there were no differences in average utilities due to substantial heterogeneity between participants. Further research is required to better understand this variation, and the results of this study could be useful in informing the design of such studies in future.

 

We look forward to having you join us!

 

Posted in | Tagged